UNSPSC 51281806: Doxorubicin

This classification denotes a doxorubicin preparation with the molecular formula C27H29NO11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80168379AG, chemically known as 3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 3-amino-2,3,6-trideoxyhexopyranoside but generally known as doxorubicin, which bears US NIH Compound Identifier 1691. European Medicines Agency schedules Doxorubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06391MIG.

UNSPSC 51281806 Doxorubicin is a Commodity code that does not align with the state and local procurement activity currently posted under it. The recent solicitations tagged to this code—Naloxone and drug deactivation systems, therapeutic pharmacy initiatives for direct-to-manufacturer prescriptions, medical and first aid supplies for fire rescue, and generic multi-source pharmaceuticals and OTC products—reflect a broad range of pharmaceutical, medical supply, and pharmacy benefit program procurements rather than doxorubicin, a specific chemotherapy agent. State and local issuing bodies posting under this code include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). The code shows activity across diverse jurisdictions and procurement vehicles, mixing single-jurisdiction IFBs, RFIs, and cooperative purchasing RFPs.

Geographic activity spans Florida, Texas, and the upper Midwest (Minnesota and Oregon), with no concentration in a single region. Representative recent opportunities include Seminole County's IFB 60459723LAS for Naloxone and drug deactivation systems (response due July 26, 2023), the City of Tampa's bid 26P00145 for medical and first aid supplies to the Fire Department Rescue Division with an estimated contract value of $700,000.00 (due March 13, 2026, with SLBE set-aside and 5 percent bid discount), and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities (proposals due March 26, 2026). The code appears to have limited activity directly relevant to doxorubicin procurement; state and local buyers using this code are acquiring broader pharmaceutical and medical supply categories through cooperative purchasing vehicles, competitive bidding, and information-gathering RFIs rather than single-source chemotherapy agents.